1st Quarter - Report

STEPTOE LLP for OREXO US, INC.

Firm
Client
Income
$230,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Alcohol and Drug Abuse ALC

Advocacy on xylazine and adultered-opioid overdose solutions and federal funding.

Foreign entity interest: Orexo US, Inc. is a subsidiary of Orexo AB. Orexo AB, based in Sweden and identified on Registration (LD-1), has an interest in policies related to pharmaceuticals.

LobbyistCovered position, as disclosed
LESLIE BELCHER —
ROWAN BOST —
MATTHEW FLYNN —

Contacted: Veterans Affairs, Dept of (VA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; White House Office; SENATE; Office of Management & Budget (OMB)

Budget/Appropriations BUD

Advocacy on xylazine and adultered-opioid overdose solutions and federal funding.

Foreign entity interest: Orexo US, Inc. is a subsidiary of Orexo AB. Orexo AB, based in Sweden and identified on Registration (LD-1), has an interest in policies related to pharmaceuticals.

LobbyistCovered position, as disclosed
LESLIE BELCHER —
ROWAN BOST —
MATTHEW FLYNN —

Contacted: Veterans Affairs, Dept of (VA); SENATE; Health & Human Services, Dept of (HHS); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES; White House Office

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.